Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.62 |
| ▸ | CTSL | P07711 | 4/20 | 0.62 |
| ▸ | CTSB | P07858 | 3/20 | 0.62 |
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151498 | 0.97 | CTSS (0.65) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL8981228 | 0.95 | CTSS (0.67) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL8981223 | 0.95 | CTSS (0.67) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL8981148 | 0.95 | CTSS (0.67) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL8981271 | 0.95 | CTSS (0.67) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL1839379 | 0.95 | CTSS (0.67) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL143763 | 0.94 | CTSS (0.57) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL18398659 | 0.88 | CTSS (0.54) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL1810276 | 0.88 | CTSS (0.54) | CTSSCTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL1809108 | 0.88 | CTSS (0.51) | CTSSCTSLCTSBCTSKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024076155-A1 | NOVEL COMPOUND AS YEATS DOMAIN INHIBITOR | 노보렉스 주식회사 | 2024-04-11 | — | — | WO | disclosed |
| US-20220009918-A1 | Chemical Compounds | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| EP-3877384-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-09-15 | — | — | EP | disclosed |
| CN-112969698-A | Chemical compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-06-15 | — | — | CN | disclosed |
| EP-3765447-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | Kezar Life Sciences (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-2934518-B1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
| US-9717714-B2 | Spirocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| WO-2017109088-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-06-29 | — | — | WO | disclosed |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-03 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20090170937-A1 | Amino Acid Derivatives | PROXIMAGEN LTD. (GB) | 2009-07-02 | — | — | US | disclosed |
| US-7550622-B2 | Cycloalkylamidoacid compounds, processes for making and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-23 | — | — | US | disclosed |
| EP-1981901-A1 | AMINO ACID DERIVATIVES | Proximagen Ltd. (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007091017-A1 | AMINO ACID DERIVATIVES | PROXIMAGEN LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-5543414-A | VIRICIDES | SYNTEX (USA) INC. (US) | 1996-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009918-A1 | Chemical Compounds | HPGDS, PTGS1, PTGER1 | CTSS 1446/4885CTSL 4010/4885CTSB 2518/4885 |
| US-20150342931-A1 | SPIROCYCLIC CETP INHIBITORS | CETP, MTTP, LCAT | CTSS 767/4885CTSL 949/4885CTSB 1182/4885 |
| US-20090170937-A1 | Amino Acid Derivatives | PARK7, PRMT7, ADCY7 | CTSS 2755/4885CTSL 3304/4885CTSB 2722/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | CTSS 920/4885CTSL 736/4885CTSB 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.